发明名称 |
Injectable flowable composition comprising buprenorphine |
摘要 |
The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis. |
申请公布号 |
US8921387(B2) |
申请公布日期 |
2014.12.30 |
申请号 |
US201113703013 |
申请日期 |
2011.06.06 |
申请人 |
RB Pharmaceuticals Limited |
发明人 |
Norton Richard L.;Watkins Andrew;Zhou Mingxing |
分类号 |
A01N43/42;A61K31/44;A61K9/00;A61K31/485;A61K47/34 |
主分类号 |
A01N43/42 |
代理机构 |
Troutman Sanders, LLP |
代理人 |
Troutman Sanders, LLP ;Schneider Ryan A.;Kleckley Troy S. |
主权项 |
1. An injectable flowable composition comprising:
(i) 8 wt % to about 22 wt % of buprenorphine free base; (ii) about 25 wt % to about 50 wt % of a poly(DL-lactide-co-glycolide) biodegradable thermoplastic polymer; wherein the polymer has an average molecular weight of about 5,000 Daltons to about 40,000 Daltons; and (iii) about 30 wt % to about 70 wt % of N-methyl-2-pyrrolidone. |
地址 |
Slough, Berkshire GB |